Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial

BACKGROUND: Survival after resection of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) still remains poor. Apatinib, a vascular endothelial cell growth factor receptor 2 inhibitor, has been shown to be safe and effective in patients with advanced HCC, so in the present study...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ann Transl Med
Главные авторы: Sun, Hui-Chuan, Zhu, Xiao-Dong, Zhou, Jian, Gao, Qiang, Shi, Ying-Hong, Ding, Zhen-Bing, Huang, Cheng, Qiu, Shuang-Jian, Ren, Ning, Shi, Guo-Ming, Sun, Jian, Ye, Qing-Hai, Huang, Xiao-Wu, Yang, Xin-Rong, Fan, Jia
Формат: Artigo
Язык:Inglês
Опубликовано: AME Publishing Company 2020
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7661881/
https://ncbi.nlm.nih.gov/pubmed/33209881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-6181
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы